Commercializing Peptides in Oncology A Decision Support Tool for Optimizing the Pipeline This report comprises defined and up to date development strategies for 145 cancer peptide drugs within the portfolio of 103 investigators, from Ceased to Marketed. The report extensively analyses 125... |
Disease Management In recent years pharmacy undergraduate teaching has changed to reflect the evolving role of the pharmacist in primary care.
Disease Management provides a holistic approach to patient care by considering the... |
Cardiotoxicity: Issues, Technologies, and Solutions for the Future At least 50 companies have a claimed product or service relevant to cardiotoxicity screening, of which 29 have some clear focus on proarrhythmic cardiotoxicity or ion channel screening. This new... |
Anti Infectives, Vol II: Antibacterials Antibacterial drugs have turned bacterial infections into treatable ailments rather than the life-threatening conditions they once were. But the effectiveness of many antibiotics is being reduced as more and more... |
Lymphoma Drug Development Strategies at Work Define Your Competition This report includes defined and up to date development strategies for
176 lymphoma therapeutic drugs (>230 projects) within the portfolio
of 106 investigators, from Ceased to Marketed. In total the report
assesses five... |
Anti-Migraine Drugs This report analyzes the US And European markets for Anti-Migraine Drugs in US$ Million. Annual forecasts are provided for the period 2006 through 2015. A six-year historic Analysis is also... |
Therapeutic Peptides in Oncology Favorable Conditions But Where to Commercialize? The discovery of new cancer therapeutics has seen a significant shift
towards biologicals as an alternative to small molecule drugs.
Alternative binding peptide molecules, derived from combinatorial
scaffold libraries, are now challenging traditional... |
Triple Target Atlas in Oncology Drug Development With the emergence of new technologies and an increased understanding of the biological basis for cancer evolution, the molecular changes that distinguish malignant-cells from normal cells are becoming increasingly apparent,... |
Competitive Outlook on HCV What to Know & Expect in R&D and Business Development The competitive business environment for the pharmaceutical market of chronic hepatitis C virus (HCV) infection is fierce and changing. The entry of Hoffmann-La Roche into this $3 billion market, previously... |
Basic Pharmacokinetics First edition Sunil S Jambhekar - Professor and Acting Chair, Department of Pharmaceutical Sciences, LECOM-Bradenton School of Pharmacy, Florida, USA and Philip Breen - Associate Professor of Pharmaceutics, College of Pharmacy, University... |
Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy With the emergence of new technologies and an increased understanding of the biological basis for cancer evolution, the molecular changes that distinguish malignant-cells from normal cells are becoming increasingly apparent,... |
Cancer Vaccines: Aim and Shoot This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates. BioSeeker has identified three... |
Handbook of Drug Administration via Enteral Feeding Tubes 1st Edition Handbook of Drug Administration via Enteral Feeding Tubes is a practical guide to the safe administration of medicines via enteral feeding tubes.
Ten chapters provide the background knowledge... |
Competitive Outlook on Lung Cancer Drug Development The Missing Handbook to New Product Planning and Portfolio Planning This report includes defined and up to date development strategies for 283 lung cancer therapeutic drugs (>317 projects) within the portfolio of 167 investigators, from Ceased to Marketed. In total... |
When Patients Becomes Plaintiffs A Primer on Drug and Medical Device Liability Runaway product liability litigation is a constant threat to manufacturers of almost any consumer product, but, as the New York Times reported in April 2006, "lawsuits over prescription drugs carry... |
Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline This report comprises defined and up to date development strategies for 239 angiogenesis affecting drugs in oncology within the portfolio of 148 corporate investigators, from Ceased to Marketed. The report... |
Cancer Vaccines Aim and Shoot This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates. BioSeeker has identified three... |
Currently Druggable in Breast Cancer A Drug Target Competitive Analysis Executive SummaryThis report aims to analyze the current and future potential of breast cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three... |
Leukemia A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking This report includes defined and up to date development strategies for 175 leukemia drugs (>250 projects) within the portfolio of 126 investigators, from Preclinical to Marketed. Leukemia drugs are further... |
Pharmaceutical Regulatory Affairs in the EU and US Regulation affects all aspects of the pharmaceutical world, from independent innovators and pharmaceutical companies, to regulatory and administrative bodies, and most importantly, to the patients taking the medicines. This report... |
Target Atlas in Oncology Drug Development: Major Tumor Types With the emergence of new technologies and an increased understanding of the biological basis for cancer evolution, the molecular changes that distinguish malignant-cells from normal cells are becoming increasingly apparent,... |
Prescribing Pharmacists A Decision Maker Emerges In five years, Kalorama Information believes the role of pharmacists currently and the demands of the US healthcare system, pharmacists will be prescribing in at least six states in five... |
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology All cancers arise as a result of the acquisition of a series of fixed DNA sequence abnormalities, mutations, many of which ultimately confer a growth advantage upon the cells in... |
Companion Biomarkers in Drug Development The term ""companion biomarker"" means that a particular diagnostic test is specifically linked to a therapeutic drug either in drug development or in the clinic. Biomarkers of disease have long... |
Adverse Drug Reactions 2nd Edition Adverse reactions to medicines continue to present a significant burden on healthcare, causing considerable morbidity and mortality. As well as being familiar with the benefits of medicines, healthcare professionals also... |
Target Atlas in Oncology Drug Development: Targeted Therapies With the emergence of new technologies and an increased understanding of the biological basis for cancer evolution, the molecular changes that distinguish malignant-cells from normal cells are becoming increasingly apparent,... |
A Decision Support Tool for Optimizing the Prostate Cancer Pipeline From Research and Development to Market This report comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. The report extensively analyses 202... |
Cancer Antibodies Competitive Positioning for Success This report aims to analyze the current and future potential of cancer antibodies by examining key fundamentals across the entire pipeline of antibody drug candidates. BioSeeker has identified three fundamental... |
Cancer Antibodies: Competitive Positioning for Success This report aims to analyze the current and future potential of cancer antibodies by examining key fundamentals across the entire pipeline of antibody drug candidates. BioSeeker has identified three fundamental... |
Currently Druggable in Prostate Cancer A Drug Target Competitive Analysis This report aims to analyze the current and future potential of prostate cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental... |
Currently Druggable in Colorectal Cancer A Drug Target Competitive Analysis Not surprisingly, an increasing number of companies have turned their attention to the cancer targeted therapy market, undoubtedly trying to emulate the blockbuster status that several brands have already achieved.
This... |
Currently Druggable in Melanoma A Drug Target Competitive Analysis This report aims to analyze the current and future potential of melanoma pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions... |
Pharmaceutical Regulatory Affairs in The Eu & US Patent expiries, tightening healthcare budgets and a stricter regulatory climate in the aftermath of the Vioxx withdrawal presented major challenges to the pharmaceutical industry in 2006. These tougher operating conditions... |